When facing the challenges of developing a treatment for a rare disease, it can be helpful for sponsors to partner with groups, such as patient advocacy organisations (PAOs), that share similar goals. PAOs are non-profit organisations that aim to improve the lives of those impacted by a given disease, with missions that can range from providing social support to influencing public policymakers — or supporting clinical research. The value of collaborating with PAOs in research has become increasingly recognised among those working to develop treatments for rare diseases.
One of the areas in which it can be particularly beneficial for sponsors in the rare disease space to partner with a PAO is in creating a patient registry. Here, we’ll explore some of the benefits of creating such a registry, as well as considerations for partnering with a PAO.
Advantages of a rare disease registry
Creating a rare disease registry can serve a number of purposes. Because there are limited numbers of patients with a given rare disease, information and data on rare diseases are often incomplete or inadequate. Patient registries, which are organised systems to collect information on a given disease, can help alleviate these difficulties. For example, registries can be used to gather data for a natural history study to gain a better understanding of the progression of a disease.
A registry can also be used as an external control arm for clinical research. This is of particular interest to patients with rare diseases, as it can help avoid the use of a placebo group in clinical trials. As a number of rare diseases do not have many options for effective treatment, participation in a clinical trial offers a source of hope for some patients — but the possibility of being included in an untreated arm may discourage them from participation.1 Using a registry to reduce the need for placebo comparison and increase the likelihood that a patient will receive the treatment may also increase their willingness to take part in a trial.
Another challenge faced in rare disease clinical studies is the difficulty finding eligible patients, given the smaller numbers of people living with a given rare disease, as well as the fact that it may be harder to identify them through electronic health records. In some cases, a registry can offer a way to find potential trial participants.
There are many other ways in which rare disease registries can be beneficial to sponsors and PAOs. Some of these include informing trial design, generating real-world data after patients have participated in a trial, and identifying diagnostic and treatment pathways to help establish best practices among physicians.
Working with a PAO
Partnering with a PAO is different from a typical business arrangement that sponsors may be familiar with. Instead of a simple business transaction, engaging in a lasting, meaningful relationship with a PAO can help to build trust with the patient community, and create lines of communication to ensure that the needs of both parties are being met. In fact, if a robust relationship is formed, the PAO can offer invaluable input beyond the patient registry alone, such as insight regarding clinical trial design that can improve recruitment and retention.
Additionally, PAOs are often run by volunteers, who in many cases are patients or caregivers of those who are affected by a disease. These individuals may be under a great deal of stress, and may not have experience in undertakings such as building a registry or working with large for-profit organisations and clinical sites. As a result, working together may require education, patience and understanding.
More specific to collaboration on registries, there may be complications in regard to data ownership. In most cases, the sponsor cannot claim sole ownership to data from a registry created in partnership with a PAO — as might otherwise be possible if the sponsor set up its own registry. Instead, it is typical for a sponsor to have exclusive rights to that data for only a set period of time before the registry becomes a community resource. However, sponsors and PAOs can be innovative in how they structure their partnership, and consider non-traditional approaches.
A complex endeavour
Collaborations between rare disease PAOs and sponsors to create registries have great potential to further the shared goals of both parties. While such partnerships may seem to be simple undertakings, there are many facets to take into consideration, such as navigating the complexities of a relationship with a PAO, choosing the correct technology and future-proofing the registry’s design. A successful rare disease registry requires careful planning and thoughtful relationship building.
Read our whitepaper to learn more about strategies for successfully partnering with a PAO to create a rare disease registry.
References:
- C. M. W. Gaasterland, M. C. Jansen – van der Weide, et al., The patient’s view on rare disease trial design – a qualitative study. Orphanet Journal of Rare Diseases. Published February 07, 2019. Accessed November 14, 2022. https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1002-z#Sec6
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel